IGBA recommendations for action to support a sustainable global pharmaceutical market for continued patient access worldwide to safe, effective and high-quality medicines (October 2019)
The positive impact that generic and biosimilar medicines have on patients and health systems (October 2019)
October 2, 2019. For decades, the brand-name drug industry has relentlessly promoted the message that any reduction in its government-protected monopolies would have detrimental effects on innovation. Members of Congress on both sides of the aisle have taken that message to heart, largely leaving pharmaceutical monopolies alone as drug prices have skyrocketed.
- IGBA Releases Trade Principles to Foster Trade in Generic and Biosimilar Medicines
- Committing to Global Health: Balancing Access and Sustainability key to success
- IGBA congratulates health Canada for decision on biologics naming that supports growing global consensus
- Statement on the Passing of Dilip Shah